Genentech sues Biogen for debt over blockbuster MS drug

Published Date: 08 Mar 2023

Roche's Genentech Inc sued Biogen MA Inc in federal court in San Francisco, alleging that Biogen owed additional patent royalties from worldwide sales of its blockbuster multiple sclerosis and Crohn's disease drug, Tysabri.

Read Full News

Latest News

Cholera Death Toll in Northeast Nigeria Rises to 90, UN Says

At least ⁠90 people have died and more than 12,000 ⁠others have been infected in a fast-spreading ⁠cholera outbreak in ‌Nigeria's conflict-hit Borno state, the U.N. Office...

Chronic Pain Conditions Burden Many With Rheumatic Diseases

Chronic overlapping pain conditions affect more than half of the adults with autoimmune rheumatic diseases, with distinct patterns seen across rheumatic disease subtypes.

Real-World Data Show Efficacy of Risankizumab in Crohn's

Risankizumab demonstrates effectiveness in achieving steroid-free clinical remission in the real-world cohort of patients with refractory Crohn's disease, with a favourable safety profile.

What Pet Owners Need to Know About New World Screwworm

Screwworm, a parasitic fly whose flesh-eating larvae feed on living animals, re-entered the U.S. Southwest in June for the first time since the 1970s, posing a threat to the...

Pre-Resection MRI May Incorrectly Stage Large Rectal Polyps

A small study finds that pre-resection pelvic MRI overstages more than 40% of large rectal polyps in patients referred for endoscopic resection.

Noninvasive Magnetic Therapy Effective in Fecal Incontinence

A novel noninvasive magnetic therapy is effective, safe, and well tolerated in patients with fecal incontinence, reducing symptom burden and disease severity.

Todays Updates

Dostarlimab Boosts Long-Term Survival in Endometrial Cancer

At 4 years, dostarlimab plus chemotherapy reduced the risk for death by two thirds among patients with dMMR/MSI-H advanced endometrial cancer, pointing to curative potential, experts say.

Todays Updates

Dostarlimab Boosts Long-Term Survival in Endometrial Cancer

At 4 years, dostarlimab plus chemotherapy reduced the risk for death by two thirds among patients with dMMR/MSI-H advanced endometrial cancer, pointing to curative potential, experts say.

Latest News

At least ⁠90 people have died and more than 12,000 ⁠others have been infected in a fast-spreading ⁠cholera outbreak in ‌Nigeria's conflict-hit Borno state, the U.N. Office...

Chronic overlapping pain conditions affect more than half of the adults with autoimmune rheumatic diseases, with distinct patterns seen across rheumatic disease subtypes.

Risankizumab demonstrates effectiveness in achieving steroid-free clinical remission in the real-world cohort of patients with refractory Crohn's disease, with a favourable safety profile.

Screwworm, a parasitic fly whose flesh-eating larvae feed on living animals, re-entered the U.S. Southwest in June for the first time since the 1970s, posing a threat to the...

A small study finds that pre-resection pelvic MRI overstages more than 40% of large rectal polyps in patients referred for endoscopic resection.

A novel noninvasive magnetic therapy is effective, safe, and well tolerated in patients with fecal incontinence, reducing symptom burden and disease severity.

News All Time

Remote Monitoring in Cirrhosis Could Reduce Admissions

A digital monitoring system for advanced cirrhosis may help detect deterioration earlier and reduce hospital admissions.

Blood Test Added to US Colorectal Cancer Screening Options

People who skip colorectal cancer screening because colonoscopy or stool testing seems too burdensome now have a blood test option from Guardant Health among recommendations...

Can Intraperitoneal Paclitaxel Improve OS in Gastric Cancer?

A phase 3 trial explores whether adding intraperitoneal paclitaxel to intravenous paclitaxel plus S-1 improves overall survival in patients with gastric cancer and peritoneal metastasis.

Pancreatic Cancer Testing Falls Short of Goals

Researchers conducted a cross-sectional electronic survey to see whether respondents were offered and completed germline genetic testing following a pancreatic ductal adenocarcinoma diagnosis.

Pancreatic Cysts: What’s the Actual Cancer Risk?

Pancreatic cysts are common and usually considered low risk — but even those lesions signal a significantly elevated and sustained cancer risk.

UTI Treatment Shift: Is Nitrofurantoin Coming Out on Top?

A large Spanish trial reports higher cure rates with 5-day nitrofurantoin therapy than with fosfomycin or pivmecillinam in women with uncomplicated UTIs.

Takeda Engaged in Antitrust Scheme to Delay Generic Constipation Drug, US Jury Finds

A U.S. jury on Monday found Takeda Pharmaceutical liable for causing about $885 million in damages by delaying a generic version of its constipation drug Amitiza through an...

Housing Instability Tied to Lower Rates of CRC Screening

Unmet health-related social needs, especially housing instability and transportation barriers, are linked to lower rates of screening for colorectal cancer among US adults.

Blood Proteins Link Poor Sleep to Increased Cancer Risk

Suboptimal sleep health, reflected in low sleep proteomic scores, is consistently associated with an increased risk for cancer, particularly gastrointestinal malignancies.

Olanzapine Cuts Radiation-Induced Nausea

The drug, widely used for chemotherapy-related nausea, may also be highly effective for symptoms caused by abdominal-pelvic radiotherapy.

Barrett Esophagus Onset Occurs Decades Before Diagnosis

Molecular clock modeling suggests that the biological onset of Barrett esophagus occurs more than 20 years before the recommended screening age.

Silent Reflux: Clinical Conundrum Solved via Proper Testing

A chronic cough without heartburn are the tell-tale signs of the condition; surgery is typically not the answer.

Zenocutuzumab OK’d for NRG1 Fusion+ Cholangiocarcinoma

The bispecific antibody has previously granted accelerated approval for advanced, unresectable, or metastatic non-small cell lung cancer and pancreatic adenocarcinoma harboring the gene fusions.

False Positive mt-sDNA Tests Could Flag Other Cancers

False-positive multi-target stool tests are linked to higher rates of noncolorectal aerodigestive cancers, suggesting further workup may be indicated in these patients.

Sigmoidoscopy Cuts Colorectal Cancer Risk in Men

Researchers randomly assign more than 100,000 adults without CRC to receive once-only sigmoidoscopy screening or no screening between 1999 and 2001. Here’s what they find.